Portfolio reviews are meant to provide clarity. They are designed to give sponsors a clear, shared understanding of how their clinical trials are progressing, where risks are emerging, and what decisions need to be made next. At their best, portfolio reviews align leadership, clinical operations, and data teams around a common picture of reality.
But for many sponsors, portfolio reviews become reconciliation exercises rather than enabling strategic conversations.
Meetings that should focus on direction and prioritization are consumed by debates over numbers, timelines, and definitions. Rather than asking what needs to change, teams spend their time explaining why reports do not match.
This shift rarely happens intentionally. It happens gradually as complexity increases and systems multiply. By the time it becomes obvious, the portfolio review has already lost much of its value.
How Portfolio Reviews Lose Their Strategic Focus
Early in a sponsor’s growth, portfolio reviews tend to be straightforward. With fewer studies and simpler operating models, it is easier to maintain a shared understanding of progress. Questions can be answered quickly, and discrepancies are visible and manageable.
As portfolios grow, that simplicity disappears.
Sponsors add studies, regions, vendors, and systems. Oversight becomes more distributed. Data flows through EDC, CTMS, eTMF, safety systems, and reporting layers, each optimized for a specific purpose. Individually, these systems perform well. Collectively, they create fragmentation.
The portfolio review becomes the point where all of this fragmentation collides.
Enrollment numbers from one report do not align with operational milestones from another. A study appears on track in one system but delayed in another. A risk flagged informally weeks ago is not reflected in any official metric. Teams arrive at the meeting with carefully prepared explanations, knowing inconsistencies will surface.
The conversation shifts from insight to justification.
Over time, this dynamic becomes expected. Portfolio reviews are no longer about understanding performance; they are about reconciling what should be a single version of the truth.
Why Reconciliation Becomes the Default
When systems are not designed to work together, people compensate.
Teams create spreadsheets to bridge gaps between EDC and CTMS. They track document readiness outside the eTMF to understand whether site activation dates are meaningful. They annotate reports with context that lives nowhere else. These workarounds are often effective in the short term, but they come at a cost.
Each workaround introduces another unofficial source of information.
Before a portfolio review, teams spend significant time validating data. They cross-check reports, confirm assumptions, and prepare narratives to explain discrepancies. The goal becomes minimizing confusion in the meeting rather than enabling productive discussion.
In the meeting itself, leaders ask reasonable questions:
- Which number is correct?
- Has this milestone actually been met?
- Why does this look different from last month?
The answers are often nuanced, dependent on definitions, timing, or system limitations.
As this pattern repeats, portfolio reviews slow down. Strategic questions are deferred until after the data is “sorted out.” Decisions are postponed. Confidence erodes.
Eventually, reconciliation is no longer an exception. It is the main event.
The Cost of Reconciliation-Focused Reviews
The most visible cost of reconciliation-heavy portfolio reviews is inefficiency. Senior leaders spend time untangling data instead of setting direction. Operational teams invest days preparing for meetings that yield limited outcomes.
But the more significant costs are less obvious.
First, trust begins to degrade. When leadership encounters conflicting information month after month, even accurate data is viewed with skepticism. Teams become cautious in their interpretations, hesitant to make strong recommendations when the underlying picture feels unstable.
Second, accountability becomes blurred. When performance issues are obscured by reporting discrepancies, it is harder to identify root causes. Delays can be attributed to data lag, system limitations, or misunderstandings rather than addressed directly.
Third, patterns across the portfolio are missed. Reconciliation forces attention downward, toward individual data points, rather than upward, toward trends. Systemic issues affecting multiple studies may remain hidden because each discrepancy is treated as a one-off problem.
Over time, portfolio reviews lose their ability to drive proactive management. They become retrospective, defensive, and constrained by uncertainty.
The Real Problem Is Not Data Accuracy
It is tempting to frame this issue as a data quality problem. When reports do not align, the assumption is often that something is wrong with the data itself.
In many cases, that assumption is incorrect.
The data in each system may be accurate within its own context. EDC reflects what has been entered and cleaned. CTMS reflects how milestones have been recorded. eTMF reflects document status based on filing rules and workflows. Each system tells a true story, but only a partial one.
What is missing is operational context.
Operational context connects data points across systems and explains how they relate to real-world progress. It answers questions such as why a milestone was recorded, whether it reflects actual readiness, and how it should be interpreted in light of other signals.
Without this context, portfolio reviews are forced to reconstruct meaning on the fly. That reconstruction is what turns reviews into reconciliation exercises.
The Difference Between Seeing Data and Understanding Progress
Having access to data does not automatically translate into visibility.
Visibility requires a shared, current understanding of where studies stand and why. It means that when a number changes, the reason for that change is clear. It means that status indicators reflect reality, not just system rules.
In effective portfolio reviews, participants do not debate whether the data is correct. They discuss what the data implies. They can move quickly from observation to action because the underlying context is already understood.
In reconciliation-focused reviews, by contrast, meaning has to be negotiated. Every metric becomes a starting point for discussion rather than a foundation for decision-making.
This distinction is subtle but critical. Sponsors may feel data-rich while still being insight-poor.
Why Standardization Alone Is Not Enough
Many sponsors respond to reconciliation challenges by standardizing definitions and metrics. They align milestone criteria, document reporting logic, and data cutoffs. These efforts are valuable and often necessary.
However, standardization addresses symptoms, not the underlying issue.
Even perfectly standardized metrics cannot capture the nuances of execution without context. A milestone achieved on paper may still represent a risk in practice. A delay may be intentional and well-managed, or it may signal deeper problems. Standard definitions do not eliminate the need for interpretation.
When portfolio reviews rely solely on standardized outputs, they still require explanation. That explanation either happens informally or consumes meeting time.
True improvement requires more than alignment. It requires integration of context into how portfolio information is viewed and discussed.
Reclaiming the Purpose of Portfolio Reviews
Portfolio reviews should help sponsors answer forward-looking questions:
- Where are we most exposed in the next 60 to 90 days?
- Which studies require leadership attention right now?
- What trade-offs do we need to make across the portfolio?
When reviews are dominated by reconciliation, these questions are overshadowed by debates about the past. Shifting the focus back to strategy requires changing how information is brought together, not just how it is reported.
This does not mean replacing existing systems. It means creating a way to see across them, so that data is interpreted consistently and context travels with the numbers.
When that happens, portfolio reviews change character. Meetings become shorter and more decisive. Teams spend less time defending data and more time discussing options. Leaders regain confidence in what they are seeing.
Most importantly, the organization moves from reacting to discrepancies to anticipating challenges.
From Reconciliation to Insight
When portfolio reviews become reconciliation exercises, it is a sign that visibility has not kept pace with complexity. The solution is not more reports or more explanation. It is a clearer, shared understanding of what the data represents in practice.
Sponsors that address this shift find that portfolio reviews once again become what they were intended to be: moments of insight, alignment, and decision-making. Clarity replaces confusion. Context replaces caveats. And portfolio reviews regain their role as a tool for guiding the organization forward, rather than a forum for debating what is true.
View our latest press release.
Related Articles:
Why Sponsors Lose Trust in Their Trial Data
Where Do Things Stand, and Other Common Pleas from Clinical Trial Sponsors